Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
about
Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase.Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics Vaborbactam and Meropenem Alone and in Combination Following Single and Multiple Doses in Healthy Adult Subjects.Meropenem-Vaborbactam: Single-Dose Pharmacokinetics and Safety in Subjects with Chronic Renal Impairment.Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.β-lactam/β-lactamase inhibitor combinations: an updateCharacterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and VaborbactamOverview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
P2860
Q40402495-4459B52C-98DA-49D6-B721-A96B3EBCEC48Q42638031-7CD76A7C-BD3A-4235-922F-7863F08D3DEBQ46243175-7FC3F7F8-F3F9-492A-A6B3-0F7D23B29741Q46306375-CC63BF50-20BD-4595-A68E-1B74BD56D05AQ47129277-66F9B392-39BD-48E1-80F0-508C03B16FA2Q47604376-8DB10C06-EB99-45AF-88C4-92EF5CFD9225Q47647043-2F74D233-D8A5-431A-B94B-FCE481574712Q50044367-B45E376A-2EF1-49E5-9DF7-65EDC14F7E7DQ50114942-9E5D62B9-FD94-47DE-B547-7E236E85D22AQ52564980-5EFAF32A-D3EE-4C1C-A2F0-BBA6319344F6Q57133147-6715E861-4C15-4A9C-A552-219848B17ED5Q58701126-69116188-BC21-4221-B2CD-9B8BA75CD09FQ58746821-AF9AE81B-DF1B-4A93-B1E5-9A83A57A810A
P2860
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@ast
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@en
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@nl
type
label
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@ast
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@en
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@nl
prefLabel
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@ast
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@en
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@nl
P2093
P2860
P356
P1476
Phase 1 Study of the Safety, T ...... 009) in Healthy Adult Subjects
@en
P2093
David C Griffith
Elizabeth E Morgan
Jeffery S Loutit
Michael N Dudley
Stephanie Durso
P2860
P304
P356
10.1128/AAC.00568-16
P407
P577
2016-08-15T00:00:00Z